Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prezista Gets New Warning On Hepatotoxicity

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA issues Medwatch Alert advising health care professionals of updated labeling for Johnson & Johnson’s protease inhibitor.

You may also be interested in...



J&J To Launch Prezista For HIV Immediately Following FDA Approval

Darunavir - formerly known as TMC-114 - in combination with ritonavir is approved for treatment-experienced adults who do not respond to other antiretrovirals.

Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign

The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.

A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025

The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel